VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | MRD-driven addition of ibrutinib to venetoclax for CLL

Lydia Scarfò, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses the results of the monotherapy and combination phases of the Phase II IMPROVE study, investigating minimal residual disease (MRD)-driven treatment intensification by sequential addition of ibrutinib to venetoclax for relapsed/refractory chronic lymphocytic leukemia (CLL). The sequential MRD-guided approach was feasible and achieved deeper responses in the majority of patients who did not achieve undetectable MRD after venetoclax treatment alone. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter